

Monash Absolute Active Trust

Hedge Fund (ASX : MAAT)



6% p.a Target
Distribution



Buy and Sell on
the ASX or direct



Long/Short
Australian Equities



Proven Track
Record¹

October 2022 Fund Update

In October, the Fund rose 7.19% (after fees). This compares to an increase of 6.04% for the S&P/ASX200 and a rise of 6.46% for the Small Ords.

There have been large swings, up and down, in the market over the last 6 months, but it has generally trended down. Smaller stocks have been particularly disappointing. During this volatile period, the Fund's flexible mandate showed its strength. It allowed us to establish a significant cash weight and proactively adjust our long and short positions when markets reached extremely overbought and oversold levels. Over this time the Fund rose 0.94% (after fees) compared to a fall of -5.41% for the S&P/ASX200 and a drop of -14.36% for the Small Ords.

In last month's update we reported that our biggest detractor was Telix Pharmaceuticals Limited (Telix, ASX: TLX) which fell 23% on its decision to withdraw its marketing authorisation application for investigational product Illuccix in Europe. The price drop was an exaggerated response during a time of market weakness.

This month TLX rose 47%, more than making back last month's fall, with the release of its September quarter business update. Total revenues for the period were \$55.3m, up 168% on the previous quarter. The next catalyst is likely to be the headline data from the pivotal trial of TLX-250-CDx for the imaging of renal cancer, due early November. Telix has always been a stock with lots of news flow. This is not surprising as its products are currently involved in about 20 clinical trials covering both company sponsored and investigator led programs.

While Telix was the star last month, positive contributions to performance from the Fund's stocks was broad based. Aside from meaningful gains in our Energy exposure, notable mentions include Lovisa Holdings Limited (ASX: LOV) and QBE Insurance (ASX: QBE). Healthia Limited (ASX: HLA) and Calix (ASX: CXL) were detractors to the portfolio, but we remain positive on both companies' outlooks.

(cont. next page)

¹ Inception date is 28 May 2021. Past performance is not indicative of future performance.

Return Summary¹ (after all fees)

1 Month	3 Months
+7.20%	+1.10%
1 Year	Since Inception
-9.90%	-0.80% pa



Our Investment team: Sebastian Correia, Simon Shields and Shane Fitzgerald

This fund is appropriate for investors with "High" and "Very High" risk and return profiles. A suitable investor for this fund is prepared to accept high risk in the pursuit of capital growth with a medium to long investment timeframe. Investors should refer to the [TMD](#) for further information.

Monash Absolute Active Trust

Hedge Fund (ASX : MAAT)

In a generally quiet month, portfolio turnover was pretty typical for the Fund. We exited two stocks due to early warning triggers, and closed two short positions that were close enough to our price targets. We established 5 new short positions based on stock specific reasons including emerging structural challenges to their businesses, solvency concerns and abrupt management exits.

Overall the portfolio's net exposure (adjusted for a couple of stocks held under cash take-over) remains around its long term average.

The portfolio remains positioned with a long bias to quality. Key long positions are in companies resilient to inflationary pressures and oversold cyclicals with dominant competitive positions. Our short book has risen slightly above its long term average weight as we continue to find compelling shorting opportunities. The portfolio's cash weight of ~20% will allow us to patiently take advantage of any continued market volatility in the upcoming months².

Monthly Portfolio Metrics

Outlook Stocks (Long)	13 Positions: 69%
Outlook Stocks (Short)	3 Positions: -5%
Event, Pair and Group (Long)	5 Positions: 24%
Event, Pair and Group (Short)	3 Positions: -4%
Cash	16%
Gross Exposure	103%
Net Exposure	84%

Portfolio Analytics Since Inception²

Sharpe Ratio	0.55
Sortino Ratio	0.97
Standard Deviation (p.a.)	16%
Positive Months	61%
Maximum Drawdown	-29%
Avg. Gross Exposure	91%
Avg. Net Exposure	79%
Avg. Beta	0.67

Return Summary Since Inception (after fees)³

CYTD	-13.31%
FYTD	8.06%
1 Month	7.19%
3 Month	1.11%
6 Month	0.91%
1 Year	-9.88%
Since Inception pa	-0.80%

²Due to lack of MAAT history, data from Monash Absolute Investment Fund (MAIF) (inception date 2 July 2012) has been used. Glossary of terms can be found on the Fund's website at www.monashinvestors.com/glossary/

³Inception date is 28 May 2021. Past performance is not indicative of future performance.

Monash Absolute Active Trust

Hedge Fund (ASX : MAAT)

For MAAT Unit Registry enquiries, please contact

Mainstream Fund Services Pty Limited

P: 1300 133 451 (in Australia)

+61 2 8259 8888 (international)

E: registry@mainstreamgroup.com

For all business development enquiries, please contact

Cameron Harris

P: +61 400 248 435

cameron@gsmcapital.com.au

For more information about MAAT and the strategy, please refer to the Monash Investors website at www.monashinvestors.com. You can also [follow us on Livewire here](#) or [subscribe to our updates here](#)

This document is prepared by Monash Investors Pty Limited ABN 67 153 180 333, AFSL 417 201 ("Monash Investors") as authorised representatives of Sanlam Private Wealth Pty Ltd ABN 18 136 960 775, AFSL 337 927 ("Sanlam") for the provision of general financial product advice in relation to the Monash Absolute Active Trust (Hedge Fund) ARSN 642 280 331 ("Fund") and authorised for release by The Trust Company (RE Services) Limited ABN 45 003 278 831, AFSL 235 150 ("Perpetual") as the responsible entity of, and issuer of units in the Fund. Monash Investors is the investment manager of the Fund. A Product Disclosure Statement ("PDS") dated 31 May 2022 together with a Target Market Determination ("TMD"), both issued by Perpetual, is available for the Fund at www.monashinvestors.com. You should obtain and consider the PDS and TMD for the Fund before deciding whether to acquire, or continue to hold, an interest in the Fund. The information provided is general information only and is not intended to provide you with financial advice, it does not consider your investment objectives, financial situation or particular needs. You should consider your own investment objectives, financial situation and particular needs before acting upon any information provided and consider seeking advice from a financial advisor if necessary. To the extent permitted by law, no liability is accepted for any loss or damage as a result of any reliance on this information. No company in Perpetual Group (Perpetual Limited ABN 86 000 431 827 and its subsidiaries) guarantees the performance of any fund or the return of an investor's capital.

You should not base an investment decision simply on past performance. Past performance is not a reliable indicator of future performance. Returns are not guaranteed and so the value of an investment may rise or fall. Total returns shown have been calculated using NAV prices after taking into account all ongoing fees and assuming reinvestment of distribution. No allowance has been made for taxation. Comparisons are provided for information purposes only and are not a direct comparison against benchmarks or indices that have the same characteristics as the Fund. Reference to Target Distributions, is a target return only. There is no guarantee the Fund will meet its investment objective. The payment of a quarterly distribution is a goal of the Fund only and neither Monash Investors or Perpetual provide any representations or warranty (whether express or implied) in relation to the payment of any quarterly cash income. The Fund reserves the discretion to amend its distribution policy.

The rating contained in this document is issued by SQM Research Pty Ltd ABN 93 122 592 036 AFSL 421913. SQM Research is an investment research firm that undertakes research on investment products exclusively for its wholesale clients, utilising a proprietary review and star rating system. The SQM Research star rating system is of a general nature and does not take into account the particular circumstances or needs of any specific person. The rating may be subject to change at any time. Only licensed financial advisers may use the SQM Research star rating system in determining whether an investment is appropriate to a person's particular circumstances or needs. You should read the product disclosure statement and consult a licensed financial adviser before making an investment decision in relation to this investment product. SQM Research receives a fee from the Fund Manager for the research and rating of the managed investment scheme.